SeaStar Medical develops cell-directed extracorporeal therapies that utilize selective cytopheretic devices to mitigate hyperinflammation in critically ill patients. This technology targets and modulates key immune cells, reducing the risk of multiorgan failure and potentially decreasing dialysis dependency and ICU stay duration.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Critically ill patients in the ICU can experience a dysregulated hyperinflammatory response to infection, trauma, or surgery, leading to multiorgan failure and potential mortality. Currently, there are limited FDA-approved therapeutic options to effectively address and resolve this destructive hyperinflammation and restore immune balance.
Solution
SeaStar Medical is focused on cell-directed extracorporeal therapies designed to modulate hyperinflammation in critically ill patients. Their Selective Cytopheretic Device (SCD) selectively targets and modulates the most highly activated neutrophils and monocytes responsible for the destructive immune response. The SCD technology aims to not only halt the cytokine storm but also potentially reverse the damage caused by destructive hyperinflammation, improving patient outcomes and reducing dependency on dialysis and time in the ICU. The device seamlessly integrates into existing hemodialysis delivery systems.
Target Audience
The primary target audience includes critically ill patients in the ICU facing organ failure due to hyperinflammation, as well as the healthcare providers and institutions that treat them.
Features
- Selective Cytopheretic Device (SCD) therapy targets hyperactivated neutrophils and monocytes.
- Extracorporeal therapy designed to modulate the destructive immune response.
- Aims to halt the cytokine storm and reverse the damage of hyperinflammation.
- Seamless integration into existing hemodialysis delivery systems.